Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG).
male breast cancer
prospective study
quality of life
symptom assessment
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
03 10 2023
03 10 2023
Historique:
received:
29
08
2022
accepted:
22
04
2023
medline:
5
10
2023
pubmed:
13
6
2023
entrez:
13
6
2023
Statut:
ppublish
Résumé
Prospective data about quality of life (QoL) in men with breast cancer (BC) are lacking. A prospective registry (EORTC10085) of men with all BC stages, including a QoL correlative study, was performed as part of the International Male Breast Cancer Program. Questionnaires at BC diagnosis included the EORTC QLQ-C30 and BR23 (BC specific module), adapted for men. High functioning and global health/QoL scores indicate high functioning levels/high QoL; high symptom-focused measures scores indicate high symptoms/problems levels. EORTC reference data for healthy men and women with BC were used for comparisons. Of 422 men consenting to participate, 363 were evaluable. Median age was 67 years, and median time between diagnosis and survey was 1.1 months. A total of 114 men (45%) had node-positive early disease, and 28 (8%) had advanced disease. Baseline mean global health status score was 73 (SD: 21), better than in female BC reference data (62, SD: 25). Common symptoms in male BC were fatigue (22, SD: 24), insomnia (21, SD: 28), and pain (16, SD: 23), for which women's mean scores indicated more burdensome symptoms at 33 (SD: 26), 30 (SD: 32), and 29 (SD: 29). Men's mean sexual activity score was 31 (SD: 26), with less sexual activity in older patients or advanced disease. QoL and symptom burden in male BC patients appears no worse (and possibly better) than that in female patients. Future analyses on impact of treatment on symptoms and QoL over time, may support tailoring of male BC management.
Identifiants
pubmed: 37310797
pii: 7197065
doi: 10.1093/oncolo/oyad152
pmc: PMC10546813
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e877-e883Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR002379
Pays : United States
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press.
Références
Breast Cancer Res Treat. 2009 May;115(2):429-30
pubmed: 18478326
Breast. 2013 Apr;22(2):197-199
pubmed: 23313328
Curr Oncol. 2010 Oct;17(5):17-21
pubmed: 20975874
Acta Oncol. 2014 Jul;53(7):958-65
pubmed: 24456505
Cancer. 1994 Jul 1;74(1):74-7
pubmed: 8004585
Methods Mol Biol. 2021;2249:247-259
pubmed: 33871848
Health Qual Life Outcomes. 2018 Jan 23;16(1):22
pubmed: 29361950
Ann Oncol. 2018 Feb 1;29(2):405-417
pubmed: 29092024
N Engl J Med. 2018 Oct 04;379(14):1385-1386
pubmed: 30281998
Psychooncology. 2020 May;29(5):851-860
pubmed: 32040237
Eur J Cancer. 2020 Jan;125:69-82
pubmed: 31838407
Cancer. 2004 Jul 1;101(1):51-7
pubmed: 15221988
Oncologist. 2020 Jun;25(6):e990-e992
pubmed: 32272505
J Clin Oncol. 2020 Jun 1;38(16):1849-1863
pubmed: 32058842
Breast Cancer Res Treat. 2022 May;193(1):95-103
pubmed: 35212906
Psychooncology. 2012 Sep;21(9):927-34
pubmed: 21695746
Breast Cancer Res Treat. 2012 Nov;136(2):495-502
pubmed: 23065002
Breast Cancer Res. 2011 Sep 29;13(5):219
pubmed: 22017761
Breast Cancer Res Treat. 2012 Jun;133(2):753-7
pubmed: 22315132
Breast Care (Basel). 2014 Feb;9(1):29-33
pubmed: 24803884
Ann Oncol. 2012 Jun;23(6):1471-4
pubmed: 22085764
Support Care Cancer. 2018 Apr;26(4):1297-1304
pubmed: 29127529